[go: up one dir, main page]

DK3292141T3 - Fusionsproteiner - Google Patents

Fusionsproteiner Download PDF

Info

Publication number
DK3292141T3
DK3292141T3 DK16721605.0T DK16721605T DK3292141T3 DK 3292141 T3 DK3292141 T3 DK 3292141T3 DK 16721605 T DK16721605 T DK 16721605T DK 3292141 T3 DK3292141 T3 DK 3292141T3
Authority
DK
Denmark
Prior art keywords
fusion proteins
fusion
proteins
Prior art date
Application number
DK16721605.0T
Other languages
English (en)
Inventor
David Bruce Baldwin
John Michael Beals
Jonathan Wesley Day
Craig Duane Dickinson
Andrew Ihor Korytko
Gregory Alan Lazar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3292141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3292141T3 publication Critical patent/DK3292141T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK16721605.0T 2015-05-07 2016-04-28 Fusionsproteiner DK3292141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
DK3292141T3 true DK3292141T3 (da) 2020-04-20

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16721605.0T DK3292141T3 (da) 2015-05-07 2016-04-28 Fusionsproteiner

Country Status (40)

Country Link
US (5) US9855318B2 (da)
EP (1) EP3292141B1 (da)
JP (1) JP6591562B2 (da)
KR (1) KR102059736B1 (da)
CN (1) CN107531806B (da)
AR (1) AR105616A1 (da)
AU (1) AU2016257659B2 (da)
CA (1) CA2981102A1 (da)
CL (1) CL2017002761A1 (da)
CO (1) CO2017011301A2 (da)
CR (1) CR20170469A (da)
CY (1) CY1122929T1 (da)
DK (1) DK3292141T3 (da)
DO (1) DOP2017000258A (da)
EA (1) EA039770B1 (da)
EC (1) ECSP17073650A (da)
ES (1) ES2799099T3 (da)
HR (1) HRP20200503T1 (da)
IL (1) IL254965B (da)
JO (1) JO3658B1 (da)
LT (1) LT3292141T (da)
MA (1) MA42037B1 (da)
MD (1) MD3292141T2 (da)
ME (1) ME03709B (da)
MX (1) MX388594B (da)
MY (1) MY183025A (da)
NZ (1) NZ736470A (da)
PE (1) PE20180507A1 (da)
PH (1) PH12017502025A1 (da)
PL (1) PL3292141T3 (da)
PT (1) PT3292141T (da)
RS (1) RS60044B1 (da)
SG (1) SG11201708194WA (da)
SI (1) SI3292141T1 (da)
SV (1) SV2017005548A (da)
TN (1) TN2018000059A1 (da)
TW (1) TWI656132B (da)
UA (1) UA122146C2 (da)
WO (1) WO2016178905A1 (da)
ZA (1) ZA201706334B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3798001A1 (en) 2016-07-27 2021-03-31 Hewlett-Packard Development Company, L.P. Horizontal interface for fluid supply cartridge having digital fluid level sensor
CN110612112B (zh) 2016-12-09 2024-03-29 阿卡斯通生物科学公司 胰岛素-fc融合物及使用方法
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CA3088763A1 (en) * 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
BR112020025287A2 (pt) 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
SG11202103045SA (en) 2018-11-20 2021-04-29 Univ Washington Split interleukin mimetics and their use
US20220143187A1 (en) * 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides
WO2021207207A2 (en) 2020-04-07 2021-10-14 Neoleukin Therapeutics, Inc. De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
EP3972987B1 (en) 2020-04-10 2023-06-07 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3189527A1 (en) * 2020-07-24 2022-01-27 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
IL301926A (en) * 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
UA129312C2 (uk) * 2020-12-14 2025-03-12 Елі Ліллі Енд Компані Водна фармацевтична композиція інсуліну ефсітора альфа та спосіб виготовлення лікарського засобу, що її містить
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) * 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
JP2025509433A (ja) * 2022-03-16 2025-04-11 北京拓界生物医薬科技有限公司 ヒトインスリン類似体、その融合タンパク質及び医薬的使用
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
JP2025522529A (ja) 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
WO2024229093A1 (en) 2023-05-03 2024-11-07 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
TW202515600A (zh) * 2023-09-20 2025-04-16 大陸商上海邁晉生物醫藥科技有限公司 一種人胰島素類似物融合蛋白的醫藥組成物及其醫藥用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
WO2025198855A1 (en) 2024-03-21 2025-09-25 Akston Biosciences Corporation Pd-l1 analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
ATE525395T1 (de) * 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
AU2003296244A1 (en) 2003-10-02 2005-05-11 Carl Zeiss Smt Ag Optical subassembly and projection objective for semiconductor lithography
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
ES2415604T3 (es) * 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
WO2009009562A2 (en) 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) * 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
KR101200659B1 (ko) 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
AU2013337250B2 (en) 2012-11-05 2017-06-22 Case Western Reserve University Long-acting single-chain insulin analogues
PT2963055T (pt) 2013-02-26 2019-07-25 Hanmi Pharm Ind Co Ltd Conugado de insulina específico ao local
AU2014236451B2 (en) * 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
CN105916877A (zh) 2014-01-20 2016-08-31 韩美药品株式会社 长效胰岛素及其用途
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
SG10201809457YA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
CO2017011301A2 (es) 2018-03-20
US20180177851A1 (en) 2018-06-28
TW201712029A (zh) 2017-04-01
US20200390865A1 (en) 2020-12-17
BR112017020502A2 (pt) 2018-07-03
TWI656132B (zh) 2019-04-11
CA2981102A1 (en) 2016-11-10
PH12017502025B1 (en) 2018-04-02
CY1122929T1 (el) 2021-10-29
US20220211818A1 (en) 2022-07-07
DOP2017000258A (es) 2017-12-31
AU2016257659A1 (en) 2017-10-12
NZ736470A (en) 2019-04-26
RS60044B1 (sr) 2020-04-30
HK1244019A1 (en) 2018-07-27
MX2017014284A (es) 2018-03-23
UA122146C2 (uk) 2020-09-25
US9855318B2 (en) 2018-01-02
MY183025A (en) 2021-02-07
MA42037B1 (fr) 2020-03-31
ES2799099T3 (es) 2020-12-14
JP2018515088A (ja) 2018-06-14
PL3292141T3 (pl) 2020-06-29
JP6591562B2 (ja) 2019-10-16
US20160324932A1 (en) 2016-11-10
IL254965A0 (en) 2017-12-31
US20250032588A1 (en) 2025-01-30
EA201792199A1 (ru) 2018-03-30
PE20180507A1 (es) 2018-03-09
EP3292141A1 (en) 2018-03-14
MD3292141T2 (ro) 2020-07-31
TN2018000059A1 (en) 2019-07-08
US12059452B2 (en) 2024-08-13
ME03709B (me) 2021-01-20
CR20170469A (es) 2017-11-14
CN107531806B (zh) 2022-06-07
AR105616A1 (es) 2017-10-25
US10709766B2 (en) 2020-07-14
JO3658B1 (ar) 2020-08-27
CL2017002761A1 (es) 2018-05-18
PH12017502025A1 (en) 2018-04-02
LT3292141T (lt) 2020-03-25
KR102059736B1 (ko) 2019-12-26
EA039770B1 (ru) 2022-03-11
CN107531806A (zh) 2018-01-02
MX388594B (es) 2025-03-20
SI3292141T1 (sl) 2020-04-30
SG11201708194WA (en) 2017-11-29
WO2016178905A1 (en) 2016-11-10
ZA201706334B (en) 2020-01-29
HRP20200503T1 (hr) 2020-06-26
PT3292141T (pt) 2020-04-22
SV2017005548A (es) 2018-04-24
ECSP17073650A (es) 2018-02-28
IL254965B (en) 2021-03-25
US11253574B2 (en) 2022-02-22
AU2016257659B2 (en) 2018-08-09
KR20170134614A (ko) 2017-12-06
EP3292141B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
DK3292141T3 (da) Fusionsproteiner
IL254516B (en) Proteins specific for cd137
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
EP3188758C0 (en) SIRP-ALPHA ANTIBODY FUSION PROTEINS
DK3197453T3 (da) Kimært protein
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
DK3107562T3 (da) P97-ids-fusionsproteiner
GB201509413D0 (en) Fusion protein
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK4089113T3 (da) Polypeptider
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
HUE043273T2 (hu) Fúziós fehérje
IL254591A0 (en) Polypeptides
EP3355931C0 (en) PROTEIN CONJUGATES
HUE056166T2 (hu) Új rovargátló fehérjék
GB201504691D0 (en) Fusion protein
DK3099791T3 (da) Protein
DK3259358T3 (da) Forøget proteinekspression
EP3688037A4 (en) IMMUNOMODULATOR FUSION PROTEINS
FI20155191L (fi) Nivel
CL2016002136A1 (es) Proteinas de fusión uti
ZA201801394B (en) Fusion protein